0001104659-24-056402.txt : 20240502
0001104659-24-056402.hdr.sgml : 20240502
20240502161629
ACCESSION NUMBER: 0001104659-24-056402
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240501
FILED AS OF DATE: 20240502
DATE AS OF CHANGE: 20240502
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mirza Nadeem Q.
CENTRAL INDEX KEY: 0002021015
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39069
FILM NUMBER: 24908526
MAIL ADDRESS:
STREET 1: 3805 OLD EASTON ROAD
CITY: DOYLESTOWN
STATE: PA
ZIP: 18902
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aprea Therapeutics, Inc.
CENTRAL INDEX KEY: 0001781983
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3805 OLD EASTON ROAD
CITY: DOYLESTOWN
STATE: PA
ZIP: 18902
BUSINESS PHONE: 617-463-9385
MAIL ADDRESS:
STREET 1: 3805 OLD EASTON ROAD
CITY: DOYLESTOWN
STATE: PA
ZIP: 18902
4
1
tm2413094-2_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-05-01
0
0001781983
Aprea Therapeutics, Inc.
APRE
0002021015
Mirza Nadeem Q.
3805 OLD EASTON ROAD
DOYLESTOWN
PA
18902
0
1
0
0
Chief Medical Officer
0
Common Stock
2024-05-01
4
A
0
6730
0.00
A
6730
D
Stock Options (Right to Purchase)
5.25
2024-05-01
4
A
0
26920
0.00
A
2034-05-01
Common Stock
29920
26920
D
These shares were granted by the Issuer as an inducement material to the Reporting Person entering into employment with the Issuer in accordance with Nasdaq Rule 5635(c)(4). These shares represent restricted stock units ("RSUs") and shall vest and be settled in the Issuer's common stock, on a one-for-one basis in three (3) equal annual installments beginning on May 1, 2025, until vested in full, subject to the Reporting Person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
The option was granted by the Issuer as an inducement material to the Reporting Person entering into employment with the Issuer in accordance with Nasdaq Rule 5635(c)(4). Twenty-five percent of these options vest on May 1, 2025, with the remaining options vesting ratably over the following 36 months, subject to the Reporting Person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
/s/ John Hamill, as Attorney-in-Fact
2024-05-02